‘A new era of growth’: As­traZeneca aims for $80B rev­enue, 20 new drugs by 2030

Last year
Pharma

ADC biotech Pheon rais­es $120M to test three as­sets in the clin­ic

Last year
Financing
Startups

GSK says long-act­ing asth­ma treat­ment clears two Phase 3 stud­ies

Last year
R&D

UK biotech rais­es £35M to de­vel­op sol­id tu­mor drugs based on ma­chine learn­ing

Last year
Financing
R&D

FDA with­draws Helsinn’s ac­cel­er­at­ed ap­proval for can­cer drug af­ter com­pa­ny’s re­quest

Last year
Pharma
FDA+

Ex­clu­sive: Mem­bers of Con­gress buy and sell stocks that would gain from bill ban­ning Chi­na biotech com­pa­nies

Last year
China

Ju­ry says As­traZeneca should pay Pfiz­er $107M+ over Tagris­so in­fringe­ment

Last year
Pharma
Law

PTC's mus­cu­lar dy­s­tro­phy drug Translar­na to get an­oth­er re­view in the EU

Last year
Pharma
FDA+

FDA ap­proves first two in­ter­change­able biosim­i­lars to Re­gen­eron's block­buster Eylea

Last year
Pharma
FDA+

Up­dat­ed: Lob­by­ing group BIO re­struc­tures staff in shake­up un­der new CEO

Last year
People
FDA+

Dyne Ther­a­peu­tics sharp­ens case for two mus­cle dis­ease ther­a­pies with up­dat­ed da­ta 

Last year
R&D

Foghorn’s $110M of­fer­ing; Novo­vax in­vestor with­draws proxy cam­paign

Last year
News Briefing

Prog­en­tos emerges with $65M for mul­ti­ple scle­ro­sis tri­als with IP from Fre­quen­cy

Last year
Financing
Startups

As­traZeneca, Am­gen tout Phase 2a Tezspire da­ta in COPD ahead of Dupix­ent de­ci­sion

Last year
R&D

Health plan start­up Cen­ti­vo ac­quires pri­ma­ry care op­er­a­tor Eden Health

Last year
Startups
Deals

Gilead­'s rare liv­er dis­ease drug im­proves symp­toms in an­oth­er Phase 3 study ahead of FDA de­ci­sion

Last year
R&D

As­traZeneca ear­marks $1.5B for end-to-end ADC fac­to­ry in Sin­ga­pore

Last year
Manufacturing

Mega start­up watch; In­ter­view with Sid­dhartha Mukher­jee; Track­ing We­govy’s long-term ef­fects; Bio­gen’s ALS flop; ...

Last year
Weekly

Rap­port, a clin­i­cal-stage neu­ro­science biotech, files for IPO

Last year
Financing
Startups

Study iden­ti­fies groups of peo­ple who mis­trust the FDA

Last year
Pharma
FDA+

Mod­er­na scores Eu­ro­pean vic­to­ry over Pfiz­er and BioN­Tech in mR­NA patent bat­tle

Last year
Pharma
Coronavirus

EMA's safe­ty com­mit­tee rec­om­mends sus­pend­ing preterm birth drugs

Last year
Pharma
FDA+

FDA re­jects liv­er can­cer drug com­bo, shares of Ko­re­an biotech tank

Last year
R&D
FDA+

Q&A: FTC’s top health­care en­forcer on phar­ma M&A, com­pa­ny growth and PBMs

Last year
Deals
Pharma
First page Previous page 155156157158159160161 Next page Last page
A service from the Financial Times